Summit, a biotech spin-out from Oxford University, has received £2.4m ($3.18m) for trials into treatment of Duchene muscular dystrophy (DMD) as part of the UK’s £26m Biomedical Catalyst Fund.
The funding is a turn of fortunes for the struggling Didcot-based spin-out, which saw its headcount axed from 40 to 13 during the UK’s recession. It has since returned to 20.
DMD is a fatal muscle-wasting condition which currently affects around 1,500 young men in the UK who are not expected…
In 2020, Stellenbosch University launched Africa's first-ever university venture fund focused on spinouts — here's how it's reshaping the country.
Global University Venturing (GUV) is where tech transfer, academic and investment experts meet to explore the latest ideas and technologies driving innovation forward. We drive the discussions and share best practices that are critical to the success of spinouts, scaleouts and innovation programmes. Our aim is to help improve the processes of bringing innovations from academia to global markets and facilitate their integration into the broader business ecosystem.
